Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 47.9% in November

Exicure, Inc. (NASDAQ:XCUR - Get Free Report) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 16,200 shares, a drop of 47.9% from the October 31st total of 31,100 shares. Currently, 2.0% of the company's stock are sold short. Based on an average daily volume of 1,620,000 shares, the short-interest ratio is presently 0.0 days.

Insider Transactions at Exicure

In other news, major shareholder Co. Ltd. Dgp purchased 237,223 shares of the company's stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average cost of $3.00 per share, with a total value of $711,669.00. Following the transaction, the insider now owns 849,223 shares in the company, valued at approximately $2,547,669. The trade was a 38.76 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.90% of the company's stock.

Exicure Stock Up 15.5 %

XCUR stock traded up $4.30 during trading on Thursday, hitting $31.99. 512,903 shares of the company's stock traded hands, compared to its average volume of 1,942,753. Exicure has a 52 week low of $1.44 and a 52 week high of $36.00. The stock has a fifty day moving average price of $5.19 and a two-hundred day moving average price of $2.23.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.